Table 5: Characteristics of patients with branch vein occlusion (BRVO) in the subconjunctival bevacizumab (SCB) group.

PatientAge (years)SexMedical
history
EyeDiagnosisPreoperative VAType of
surgery
Postoperative
interventions
Onset of
BRVO
TreatmentFinal VAFinal IOP
(mm Hg)

173FNoneOSPOAG20/40Phacotrab.Needling
goniopuncture
suture lysis
SCB
14.8 weeks postsurgery
8.8 weeks after SCB
Focal laser20/308

281MHTN
BRVO OD
ODPOAG20/50Phaco-NPGSSCB
goniopuncture
suture lysis
7.8 weeks postsurgery
6.8 weeks after SCB
IVTA20/15010

380MHyperchol.OSPOAG20/40Phacotrab.SCB9.7 weeks postsurgery
8.3 weeks after SCB
Focal laser20/4014

HTN: hypertension; hyperchol.: hypercholesterolemia; POAG: primary open-angle glaucoma; phacotrab.: phacotrabeculectomy; NPGS: nonpenetrating glaucoma surgery; SCB: subconjunctival injection of bevacizumab; IVTA: intravitreal injection of triamcinolone acetonide; VA: visual acuity.